All In Biotech

Drug Trial Radar · NCT03656562

Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients

A Placebo-controlled, Patient and Investigator Blinded, Randomized Parallel Cohort Study to Assess Pharmacodynamics, Pharmacokinetics, Safety, Tolerability and Preliminary Clinical Efficacy of VAY736 and CFZ533 in Patients With Systemic Lupus Erythematosus (SLE)

Last checked: Nov 19, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 107 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

107

Actual

Start

Dec 19, 2018

Primary completion

Jul 27, 2022

Study completion Apr 28, 2025

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Sep 4, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to evaluate the safety, tolerability, pharmacokinetics and therapeutic efficacy of treatment with either VAY736 (ianalumab) or CFZ533 (iscalimab) in patients with systemic lupus erythematosus (SLE) to enable further development of these compounds as treatment in this disease population

Conditions

  • Systemic Lupus Erythematosus (SLE)

Interventions

  • VAY736Drug

    150 mg powder in vial for solution for injection; after reconstitution to 150 mg/mL per vial, a dose of 300 mg

  • VAY736 PlaceboDrug

    solution for injection; 0 mg/mL administered as 2 mL s.c. injection

  • CFZ533Drug

    150 mg/mL as concentrate in vial for infusion, administered at a dose of 10 mg/kg as i.v. infusion

  • CFZ533 PlaceboDrug

    Placebo as concentrate in vial for infusion, administered at a dose of 10 mg/kg as i.v. infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With SLE Responder Index (SRI)-4 Response Status at Week 29 With Reduced Steroid Dose Maintained Between Weeks 17 and 29Time frame: Baseline, Week 17 to Week 29

Locations

31 sites in 15 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Caba, Argentina

  • Novartis Investigative Site

    Clayton, Victoria, Australia

  • Novartis Investigative Site

    Shanghai, China

  • Novartis Investigative Site

    Guangzhou, Guangdong, China

  • Novartis Investigative Site

    Nanjing, Jiangsu, China

  • Novartis Investigative Site

    Prague, Czechia

  • Novartis Investigative Site

    Pessac, France

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Freiburg im Breisgau, Baden-Wurttemberg, Germany

  • Novartis Investigative Site

    Budapest, Hungary

  • Novartis Investigative Site

    Debrecen, Hajdu Bihar Megye, Hungary

  • Novartis Investigative Site

    Ramat Gan, Israel

  • Novartis Investigative Site

    Nagoya, Aichi-ken, Japan

  • Novartis Investigative Site

    Nagoya, Aichi-ken, Japan

  • Novartis Investigative Site

    Chuo Ku, Tokyo, Japan

  • Novartis Investigative Site

    Shinjuku Ku, Tokyo, Japan

  • Novartis Investigative Site

    Shinjuku-ku, Tokyo, Japan

  • Novartis Investigative Site

    Bydgoszcz, Poland

  • Novartis Investigative Site

    Poznan, Poland

  • Novartis Investigative Site

    Warsaw, Poland

  • Novartis Investigative Site

    Moscow, Russia

  • Novartis Investigative Site

    Saint Petersburg, Russia

  • Novartis Investigative Site

    Yekaterinburg, Russia

  • Novartis Investigative Site

    Gwangju, South Korea

  • Novartis Investigative Site

    Barcelona, Spain

  • Novartis Investigative Site

    Barcelona, Spain

  • Novartis Investigative Site

    Taichung, Taiwan

  • Novartis Investigative Site

    Taichung, Taiwan

  • Novartis Investigative Site

    Taichung, Taiwan ROC, Taiwan

  • Novartis Investigative Site

    Bangkok, Thailand

  • Novartis Investigative Site

    Bangkok, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.